Adverse events with checkpoint inhibitors tied to lung-cancer survival

Reuters Health - 10/11/2020 - Treatment of non-small-cell lung cancer (NSCLC) with immune-checkpoint inhibitors may prompt multisystem immune-related adverse events, but this appears to be good news, a retrospective study in JAMA Oncology suggests. "There is a growing body of literature showing that the development of immune-related adverse events (irAEs) may associate with improved survival outcomes from immunotherapy for NSCLC," said Dr. Jarushka Naidoo of Johns Hopkins University, in Baltimore, Maryland. "For the first time," she told Reuters Health by email, "we show that the development of more than one irAE may be associated with an incremental improvement in survival outcomes... even when adjusting for treatment duration." To characterize irAEs linked to anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune-checkpoint inhibitors (ICIs), Dr. Naidoo, also at Beaumont Hospital in Dublin, Ireland, and colleagues studied data...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 10 November, 202020 November, 2020